RESUMO
PURPOSE: To describe Health-Related Quality of Life (HRQoL) and to identify the association between sociodemographic, clinical and psychosocial factors, and self-reported HRQoL among NHL survivors. METHODS: The data of the cancer registry specialized in hematological malignancies in Côte d'Or (France) were used to identify all patients diagnosed with follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) from 2010 to 2017. Patients were invited to complete SF-12 and other questionnaires. RESULTS: The HRQoL of NHL survivors was poorer than that of the French general population (p < 0.05) in vitality (48 vs. 56), general health (56 vs. 63), role physical scores (60 vs. 70), role emotional scores (64 vs. 72) and the Mental Component Scale (45 vs. 49). The mean difference in physical functioning decreased per unit increase in age (ß = -1.1 (0.3); p < 0.001). Men had better vitality than women (ß = 12.4 (6.1); p = 0.04) and the high education level was associated with greater role emotional scores (ß = 14.1 (5.4); p = 0.01). Symptoms of anxiety and depression were associated with poorer HRQoL. The satisfaction of social support was associated with significantly greater scores on mental health (ß = 17.3 (5.1); p = 0.001) and social functioning (ß = 15.7 (7.8); p = 0.04). Socioeconomic deprivation was associated with poorer general health (ß = -12.8 (5.2); p = 0.01). CONCLUSIONS: From 3 to 11 years post-diagnosis, the main factors found to be associated with poor HRQoL of NHL survivors were age, sex, presence of anxiety, depression and economic problems. These findings suggest the need for supportive care to improve HRQOL and the consideration of these problems when developing care plans for NHL survivors.
RESUMO
Background: Peer review to assess the quality of documentation is essential, as it provides a framework for constructive feedback, using evaluators with similar qualifications to increase acceptability. Objective: To determine the feasibility of implementing a peer review continuous quality improvement program for pharmacists' documentation at the Montreal Children's Hospital. Methods: A prospective, single-centre mixed-methods feasibility study was conducted (from January to June 2021) to evaluate the practicality and acceptability of a peer review program (PRP) for assessing the quality of pharmacists' documentation. A peer review committee of 5 pharmacists evaluated their peers' clinical notes using a standardized assessment tool. Practicality was determined through the time required for administrative and evaluative tasks and the resources needed for each evaluation cycle. Acceptability was determined through pooled quantitative data related to pharmacists' perceived relevance of the PRP, confidence in their peers, and satisfaction with the evaluation process. Qualitative data collected through surveys, a focus group, and semistructured individual interviews helped to further explain the results. Results: A total of 37.4 hours was required to complete both administrative and evaluative tasks in one peer review cycle, which respected the budgeted cut-off for practicality. Acceptability was also achieved, given that more than 80% of survey respondents found the PRP relevant to their practice, were confident in their peers, and were satisfied with the PRP. Qualitative results showed that participants found the PRP to be instructive and that qualitative feedback was preferred over a grade issued as a percentage. Conclusion: This study showed that it is feasible to implement a PRP to assess the quality of pharmacists' documentation. To ensure success, it is key that documentation objectives and department resources be predefined.
Contexte: L'évaluation par les pairs afin d'évaluer la qualité de la documentation est essentielle, car elle fournit un cadre pour une rétroaction constructive émise par des évaluateurs ayant des qualifications similaires afin d'augmenter l'acceptabilité. Objectif: Déterminer la faisabilité d'implanter un programme d'évaluation par les pairs en continu de la qualité de la documentation des pharmaciens à l'Hôpital de Montréal pour Enfants. Méthodes: Une étude de faisabilité prospective, monocentrique et de méthodes mixtes a été menée (de janvier à juin 2021) pour évaluer la praticité et l'acceptabilité d'un programme d'évaluation par les pairs (PEP) ayant pour but d'évaluer la qualité de la documentation des pharmaciens. Un comité d'évaluation par les pairs composé de 5 pharmaciens a évalué les notes cliniques de leurs pairs à l'aide d'un outil d'évaluation standardisé. La praticité a été déterminée par le temps requis pour les tâches administratives et d'évaluation et les ressources nécessaires pour chaque cycle d'évaluation. L'acceptabilité a été déterminée grâce à des données quantitatives regroupées liées à la pertinence perçue du PEP par les pharmaciens, à la confiance envers leurs pairs et à la satisfaction à l'égard du processus d'évaluation. Les données qualitatives recueillies par le biais de sondages, d'un groupe de discussion et d'entretiens individuels semi-structurés ont permis d'expliquer davantage les résultats. Résultats: Un total de 37,4 heures a été nécessaire pour accomplir les tâches administratives et d'évaluation dans un cycle d'évaluation par les pairs, ce qui respectait le seuil budgété pour des raisons pratiques. L'acceptabilité a également été atteinte puisque plus de 80 % des répondants au sondage trouvaient le PEP pertinent pour leur pratique, avaient confiance en leurs pairs et étaient satisfaits du programme. Les résultats qualitatifs ont montré que les participants trouvaient le PEP instructif et que la rétroaction sous forme de commentaires état préférée à une note émise en pourcentage. Conclusion: Cette étude a démontré qu'il est possible de mettre en place un PEP pour évaluer la qualité de la documentation des pharmaciens. Pour garantir sa réussite, il est essentiel de prédéfinir les objectifs de documentation et les ressources départementales à disposition.
RESUMO
INTRODUCTION: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) have been characterized with the use of oral bisphosphonates in osteoporosis and zoledronate in oncology. Uncertainties remain, though, with the occurrence of BRONJ related to the use of zoledronate in osteoporosis. OBJECTIVES: We aimed to estimate the incidence and characterize the risk factors of zoledronate-associated BRONJ in osteoporosis as compared with oral bisphosphonates in real life setting. METHODS: Cases of BRONJ associated with zoledronate, alendronate or risedronate were extracted from the French pharmacovigilance database up to 2020. The incidence of BRONJ was estimated as their respective numbers related to cases of BRONJ in patients treated with bisphosphonates for osteoporosis, over the same period, according to the Medic'AM database. RESULTS: Between 2011 and 2020, BRONJ incidence with zoledronate was 9.6/100,000 patient-year (PY), significantly higher than with alendronate (5.1/100,000 PY, P<0.001), and risedronate (2.0/100,000 PY, P<0.001). The number of patients treated with bisphosphonates has steadily decreased by 44.5% over 10 years. Meanwhile, the incidence of BRONJ decreased (5.8/100,000 PY in 2011; 1.5/100,000 in 2020), although a rebound was observed in 2018, including 47.6% of BRONJ following denosumab. Apart from classical risk factors, recent dental cares stood out in more than 40% of BRONJ, and zoledronate had a shorter exposure time than oral bisphosphonates. CONCLUSIONS: In a real-life setting, our data confirm that zoledronate-associated BRONJ in osteoporosis is scarce, seeming slightly more common compared with oral bisphosphonates. We also raise awareness of dental care guidelines and greater vigilance when using bisphosphonates in patients with previous exposure to denosumab.
Assuntos
Osteonecrose da Arcada Osseodentária Associada a Difosfonatos , Conservadores da Densidade Óssea , Osteoporose , Humanos , Ácido Zoledrônico/efeitos adversos , Alendronato/efeitos adversos , Conservadores da Densidade Óssea/efeitos adversos , Ácido Risedrônico , Denosumab , Farmacovigilância , Incidência , Difosfonatos/efeitos adversos , Osteoporose/tratamento farmacológico , Osteoporose/epidemiologia , Osteoporose/induzido quimicamente , Osteonecrose da Arcada Osseodentária Associada a Difosfonatos/diagnóstico , Osteonecrose da Arcada Osseodentária Associada a Difosfonatos/epidemiologia , Osteonecrose da Arcada Osseodentária Associada a Difosfonatos/etiologia , Fatores de RiscoRESUMO
BACKGROUND: The excess mortality observed in Acute Myeloblastic Leukaemia (AML) patients, partly attributed to unequal access to curative treatments, could be linked to care pathways. METHODS: We included 1039 AML incident cases diagnosed between 2012-2016 from the 3 French blood cancer registries (3,625,400 inhabitants). We describe patients according to age, the medical entry unit and access to the specialised haematology unit (SHU) during follow-up. Multivariate logistic regression model was done to determine the association between covariables and access to SHU. A total of 713 patients (69%) had access to SHU during care. RESULTS: The most common care pathway concerned referral from the general practitioner to SHU, n = 459(44%). The univariate analysis observed a downward trend for the most deprived patients. Patients who consulted in SHU were younger (66 years vs. 83, p < 0.001), and 92% had access to cytogenetic analysis (vs. 54%, p < 0.001). They also had less poor prognosis AML-subtypes (AML-MRC, t-AML/MDS and AML-NOS) (38% vs. 69%); 77% with de novo AML (vs. 67%, p < 0.003)], more favourable cytogenetic prognostic status (23% vs. 6%, p < 0.001), less comorbidities (no comorbidity = 55% vs. 34%, p < 0.001) and treatments proposed were curative 68% (vs. 5.3%, p < 0.001). Factors limiting access to SHU were age over 80 years (OR, 0.14; 95% CI, 0.04-0.38), severe comorbidities (OR, 0.39; 95% CI, 0.21-0.69), emergency unit referral (OR, 0.28; 95% CI, 0.18-0.44) and non-SHU referral (OR, 0.12; 95% CI, 0.07-0.18). Consultation in an academic hospital increased access to SHU by 8.87 times (95% CI, 5.64-14.2). CONCLUSION: The high proportion of access to cytogenetic testing and curative treatment among patients admitted to SHU, and the importance of early treatment in AML underlines the importance of access to SHU for both diagnosis and treatment.
Assuntos
Hematologia , Leucemia Mieloide Aguda , Humanos , Idoso de 80 Anos ou mais , Leucemia Mieloide Aguda/diagnóstico , Leucemia Mieloide Aguda/epidemiologia , Leucemia Mieloide Aguda/terapia , Prognóstico , Análise Citogenética , Assistência ao PacienteRESUMO
The basal ganglia (BG) inhibit movements through two independent circuits: the striatal neuron-indirect and the subthalamic nucleus-hyperdirect pathways. These pathways exert opposite effects onto external globus pallidus (GPe) neurons, whose functional importance as a relay has changed drastically with the discovery of two distinct cell types, namely the prototypic and the arkypallidal neurons. However, little is known about the synaptic connectivity scheme of different GPe neurons toward both motor-suppressing pathways, as well as how opposite changes in GPe neuronal activity relate to locomotion inhibition. Here, we optogenetically dissect the input organizations of prototypic and arkypallidal neurons and further define the circuit mechanism and behavioral outcome associated with activation of the indirect or hyperdirect pathways. This work reveals that arkypallidal neurons are part of a novel disynaptic feedback loop differentially recruited by the indirect or hyperdirect pathways and that broadcasts inhibitory control onto locomotion only when arkypallidal neurons increase their activity.
Assuntos
Globo Pálido/citologia , Locomoção/fisiologia , Vias Neurais , Sinapses , Animais , Feminino , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Neurônios , Optogenética , Núcleo Subtalâmico/citologiaRESUMO
Gram positive bacteria produce cell envelope macroamphiphile glycopolymers, i.e. lipoteichoic acids or lipoglycans, whose functions and biosynthesis are not yet fully understood. We report for the first time a detailed structure of lipoteichoic acid isolated from a Streptomyces species, i.e. Streptomyces hygroscopicus subsp. hygroscopicus NRRL 2387T. Chemical, MS and NMR analyses revealed a polyglycerolphosphate backbone substituted with α-glucosaminyl and α-N-acetyl-glucosaminyl residues but devoid of any amino-acid substituent. This structure is very close, if not identical, to that of the wall teichoic acid of this organism. These data not only contribute to the growing recognition that lipoteichoic acid is a cell envelope component of gram positive Actinobacteria but also strongly support the recently proposed hypothesis of an overlap between the pathways of lipoteichoic acid and wall teichoic acid synthesis in these bacteria. S. hygroscopicus lipoteichoic acid induced signalling by human innate immune receptor TLR2, confirming its role as a microbe-associated molecular pattern. Its activity was partially dependant on TLR1, TLR6 and CD14. Moreover, it stimulated TNF-α and IL-6 production by a human macrophage cell line to an extent similar to that of Staphylococcus aureus lipoteichoic acid. These results provide new clues on lipoteichoic acid structure/function relationships, most particularly on the role of the polyglycerolphosphate backbone substituents.
Assuntos
Fatores Imunológicos/química , Fatores Imunológicos/farmacologia , Lipopolissacarídeos/química , Lipopolissacarídeos/farmacologia , Modelos Moleculares , Streptomyces/química , Ácidos Teicoicos/química , Ácidos Teicoicos/farmacologia , Citocinas/biossíntese , Células HEK293 , Humanos , Fatores Imunológicos/biossíntese , Fatores Imunológicos/isolamento & purificação , Lipopolissacarídeos/biossíntese , Lipopolissacarídeos/isolamento & purificação , Transdução de Sinais/efeitos dos fármacos , Streptomyces/metabolismo , Relação Estrutura-Atividade , Ácidos Teicoicos/biossíntese , Ácidos Teicoicos/isolamento & purificação , Receptor 2 Toll-Like/metabolismoRESUMO
BACKGROUND: End stage dementia is a particularly difficult aspect of care for patients with Alzheimer's disease and related dementias. In care institutions, caregivers and family are concerned by treatment decision-making for an acute life threatening complication occurring in Alzheimer patients at the end of life. How should the best treatment pathway be decided: to treat or not to treat? Which arguments are used for decision-making? These are mainly ethical questions which are currently difficult to express and investigate. METHODS/DESIGN: Cross sectional multicentre study of clinical cases involving 67 health centres (university hospitals, general hospitals, local hospitals and homes for the elderly) in the east of France. The method was based on the "card sorting" technique, with a set of 36 cards, each labelled with a different item relating to arguments for treatment decision-making. For each clinical case, medical staff and carers expressed in a meeting the pieces of information which they believed had been taken into account in the decision. Each participant received a card game, selected fewer than ten and ranked them according to the importance they attached to each one. All selected cards were then put on the table anonymously for participants, respecting the order of importance of the cards in each pile. Lastly, all games were photographed together in order to analyse occurrence and order frequencies. The cards were then classified on the table by frequency to open the discussion. Discussion time, which was conducted by the head carer of the department, concerned the clinical situation of the patient based on the shared responses. DISCUSSION: During team meetings, the "card sorting" method was quickly adopted by professionals as a tool to assist with discussion beyond the context of the study. The participants were not compelled to mention their feelings in relation to a case, and it is significant that the anonymity which we tried to maintain so that each person felt "listened to" without value judgement was very often discarded by the individuals themselves.
RESUMO
BACKGROUND: The clinical characteristics of frail older patients with advanced heart failure have scarcely been studied. OBJECTIVE: To describe this population and to identify some prognostic factors of mortality. METHODS: 104 patients aged 75 years and older hospitalized with refractory heart failure were enrolled in a prospective multicentric study. RESULTS: Mean age was 87.2 +/- 5.3 years. Dyspnea (79.8%), crepitant rales (76.9%) and peripheral edema (73.1%) were particularly frequent. Signs of low cardiac output such as renal insufficiency (46.9%), cutaneous low flow (40.4%), and systolic hypotension (< or =100 mm Hg) (24.3%) were observed less often. Signs of cognitive impairment including anxiety (55.4%), sleep disorders (43.7%) and delirium (35.5%) were frequent. Asthenia and chronic pain were noted in 92.3 and 37.5% of cases, respectively. Mortality rates were 32.7, 59.6 and 71.2% during hospitalization, at 6 months and at 12 months, respectively. According to the multivariate Cox model, six significant factors suggesting a poor prognosis were observed: chronic renal insufficiency, past neuropsychological pathology, long-term treatment with nitrates, presence of edema, low cutaneous flow, and pain. The ability to sit on a chair was the only significant factor associated with a good prognosis. CONCLUSION: Our study identified some clinical and prognostic factors which had been observed in very old patients with refractory heart failure. Pain management has to be a priority in these patients in order to improve their quality of life.